Neboglamine hydrochloride

Cat. No.: HY-114753A

CAS No.: 2759182-59-5

Molecular Formula: $C_{13}H_{25}ClN_2O_3$

Molecular Weight: 292.8

Target: iGluR

Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research[1].

In Vivo

Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats[1]
Dosage:	20 mg/kg
Administration:	Subcutaneous injection
Result:	Increased neuronal activity in brain regions, prefrontal cortex (PFCX) from 38.5 to 121.3, nucleus accumbens (NAc) from 14.5 to 69.1 and lateral septal nucleus (LSN) from 16.2 to 73.1 but no effect on dorsolateral striatum (DL-STR) compared to the control group. Significantly inhibited phencyclidine-induced hypermobility.

Animal Model:	Male Wistar rats[1]
Dosage:	0.3 mg/kg, 3 mg/kg, 30 mg/kg
Administration:	Oral administration
Result:	Reduced frequency of PCP-induced hypermobility and stereotyped behaviour in a dose-dependent manner and the dose inhibited stereotyped behaviour (0.3 mg/kg) was lower than the dose inhibited motor activity (3 mg/kg).

REFERENCES

[1]. Riccardo Chiusaroli, et al. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in

the rat. Pharmacol Res. 2010 May;61(5):430-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA